Jan 24, 2025 · Novo Nordisk reported today that amycretin, an investigational glucagon-like peptide-1 (GLP-1) and amylin receptor agonist, led to significant weight reductions in individuals with overweight or obesity in a phase 1b/2a clinical trial. 1 The randomized, placebo-controlled 5-part trial enrolled 125 adults and assessed the safety, tolerability, pharmacokinetics, and proof-of-concept of once ...

3 days ago · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks. These topline results show early potential for the drug candidate to surpass the efficacy of Eli Lilly’s Zepbound (tirzepatide), one of its major ...

4 days ago · Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight individuals. ... Subjects receiving the therapy experienced notable weight loss, with an estimated reduction of 9.7% on 1.25mg over 20 weeks, 16.2% on 5mg over 28 weeks, and 22% on 20mg over a 36-week period.

Jan 24, 2025 · One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday ...

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...

Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 drug Zepbound may still have an edge over Wegovy.

Sep 11, 2024 · Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for...

Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

Sep 23, 2024 · An experimental new pill from Novo Nordisk, called amycretin, could cause substantial weight loss in people with obesity. The once-daily oral medication is in the same class as the blockbuster obesity and diabetes medications, Ozempic and Mounjaro.

Sep 10, 2024 · A daily weight loss pill from Novo Nordisk was shown to lower body weight by up to 13% after three months in a Phase 1 clinical trial, according to findings presented Tuesday at the European...